Synthesis of conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 7, 2000, Pages 681-684

  Baraldi, Pier Giovanni ^a   Romagnoli, Romeo ^a   Tabrizi, Mojgan Aghazadeh ^a   Falzoni, Simonetta ^a   Di Virgilio, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; DRUG ANALOG; PURINE P2X RECEPTOR;

ARTICLE; CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; PARTIAL DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; CALCIUM; HUMANS; MACROPHAGES; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034599539     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00083-4     Document Type: Article

References (24)

1. For reviews see: (a) Burnstock, G. Neuropharmacology 1997, 36, 1127; (b) Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. M.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. Pharmacol. Rev. 1996, 46, 143; (c) Di Virgilio, F.; Chiozzi, P.; Falzoni, S.; Ferrari, D.; Sanz, M. J.; Venketaraman, V.; Baricoldi, O. R. Cell Death and Differentiation 1998, 5, 191; (d) Fischer, B. Exp. Opin. Therap. Pat. 1999, 9, 385.
2. For reviews see: (a) Burnstock, G. Neuropharmacology 1997, 36, 1127; (b) Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. M.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. Pharmacol. Rev. 1996, 46, 143; (c) Di Virgilio, F.; Chiozzi, P.; Falzoni, S.; Ferrari, D.; Sanz, M. J.; Venketaraman, V.; Baricoldi, O. R. Cell Death and Differentiation 1998, 5, 191; (d) Fischer, B. Exp. Opin. Therap. Pat. 1999, 9, 385.
3. For reviews see: (a) Burnstock, G. Neuropharmacology 1997, 36, 1127; (b) Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. M.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. Pharmacol. Rev. 1996, 46, 143; (c) Di Virgilio, F.; Chiozzi, P.; Falzoni, S.; Ferrari, D.; Sanz, M. J.; Venketaraman, V.; Baricoldi, O. R. Cell Death and Differentiation 1998, 5, 191; (d) Fischer, B. Exp. Opin. Therap. Pat. 1999, 9, 385.
4. For reviews see: (a) Burnstock, G. Neuropharmacology 1997, 36, 1127; (b) Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. M.; Harden, T. K.; Jacobson, K. A.; Leff, P.; Williams, M. Pharmacol. Rev. 1996, 46, 143; (c) Di Virgilio, F.; Chiozzi, P.; Falzoni, S.; Ferrari, D.; Sanz, M. J.; Venketaraman, V.; Baricoldi, O. R. Cell Death and Differentiation 1998, 5, 191; (d) Fischer, B. Exp. Opin. Therap. Pat. 1999, 9, 385.
5. Di Virgilio, F.; Falzoni, S.; Mutini, C.; Sanz, J. M.; Chiozzi, P. Drug Dev. Res. 1998, 45, 207.
6. (a) Dubyak, G. B.; Clifford, E. E.; Humphreys, B. D.; Kertesy, S. B.; Martin, K. A. Drug. Dev. Res. 1996, 39, 269;
7. (b) Ferrari, D.; Los, M.; Bauer, M. K. A.; Vandenabeele, P.; Wesselborg, S.; Schulzelohoff, K. FEBS Lett. 1999, 447, 71;
8. (c) Schulzelohoff, E.; Hugo, C.; Rost, S.; Arnold, S.; Gruber, A.; Brune, B.; Sterzel, R. B. Am. J. Physiol. 1998,44, 962;
9. (d) Coutinho Silva, R.; Persechini, P. M.; Bisaggio, R. D.; Perfettini, J. L.; Neto, A. C. T. D.; Kanellopoulos, J. M.; Motta Ly, I.; Dautry Varsat, A.; Ojcius, D. M. Am. J. Physiol. 1999, 45, 1139.
10. Suprenant, A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G. Science 1996, 272, 735.
11. Gargett, C. E.; Wiley, J. S. Br. J. Pharmacol. 1997, 120, 1483.
12. Hidaka, H.; Yokokura, H. Adv. Pharmacol. 1996, 36, 193.
13. Kawamura, K.; Grabowski, D.; Krivacic, K.; Hidakan, H.; Ganapathi, R. Biochem. Pharmacol. 1996, 12, 1903.
14. Ricouart, A.; Gesquire, J. C.; Tartar, A.; Sergheraert, C. J. Med. Chem. 1991, 34, 73.
15. (a) Whaley, W. M.; Govindachari, T. R. Org. React. 1951, 6, 151;
16. (b) Cox, E. D.; Cook, J. M. Chem. Rev. 1995, 6, 1797.
17. Verschueren, K.; Toth, G.; Tourwè, D.; Lebl, M.; Van Binst, G.; Hruby, V. Synthesis 1991, 458.
18. For the synthesis of the isoquinoline-5-sulfonyl chloride see: Morikawa, A.; Sone, T.; Asano, T. J. Med. Chem. 1989, 32, 42; The quinoline-8-sulfonyl chloride has been prepared following the procedure reported by Edinger, A. Chem. Ber. 1908, 41, 937; while for the preparation of quinoline-5-sulfonyl chloride see: Albert, A.; Garlin, G. B. J. Chem. Soc. 1959, 2384. The naphtalene-1-sulfonyl chloride is commercially available.
19. For the synthesis of the isoquinoline-5-sulfonyl chloride see: Morikawa, A.; Sone, T.; Asano, T. J. Med. Chem. 1989, 32, 42; The quinoline-8-sulfonyl chloride has been prepared following the procedure reported by Edinger, A. Chem. Ber. 1908, 41, 937; while for the preparation of quinoline-5-sulfonyl chloride see: Albert, A.; Garlin, G. B. J. Chem. Soc. 1959, 2384. The naphtalene-1-sulfonyl chloride is commercially available.
20. For the synthesis of the isoquinoline-5-sulfonyl chloride see: Morikawa, A.; Sone, T.; Asano, T. J. Med. Chem. 1989, 32, 42; The quinoline-8-sulfonyl chloride has been prepared following the procedure reported by Edinger, A. Chem. Ber. 1908, 41, 937; while for the preparation of quinoline-5-sulfonyl chloride see: Albert, A.; Garlin, G. B. J. Chem. Soc. 1959, 2384. The naphtalene-1-sulfonyl chloride is commercially available.
21. (a) Jung, M. E.; Lyster, M. A. J. Chem. Soc., Chem. Commun. 1978, 315;
22. (b) Olah, G. A.; Narang, S. C.; Gupta, B. G. B.; Malhotra, R. J. Org. Chem. 1979, 44, 1247.
23. 2+ concentration was determined with the 340:380 nm excitation ratio at an emission wavelenght of 500 nm. All experiments were repeated three times.
24. -1: 3434, 1647, 1458, 1378, 1225, 1174, 828. Elemental analysis (calcd): C. 63.40; H. 4.62; N. 9.73; S. 8.91 (found): C. 62.98; H. 4.43; N. 9.42; S. 8.71.